Navigation Links
Micell Technologies Enrolls First Patient in CE Mark DESSOLVE II Study of MiStent™ Drug-Eluting Coronary Stent (DES)
Date:2/17/2011

ded to precisely and consistently control drug elution and the duration of polymer exposure.  As a result, the MiStent DES is intended to deliver a precise therapeutic solution for coronary artery disease with the potential to avoid the long-term safety concerns associated with current drug-eluting stents.

Using an approved drug (sirolimus) and polymer (PLGA), Micell's patented supercritical fluid technology allows a carefully controlled drug/polymer coating to be applied to a bare-metal stent. Micell is leveraging the strengths of Eurocor's (CE Marked) Genius® MAGIC Cobalt Chromium Coronary Stent System, a state-of-the-art bare-metal stent, shown to demonstrate excellent deliverability, conformability and flexibility. In GLP pre-clinical trials, the drug completely elutes and the polymer is eliminated from the stent within 45 to 60 days in vivo, resulting in a bare-metal stent.

The MiStent Drug Eluting Coronary Stent System is an investigational device.  It is not yet approved or available for sale in any market.

About Micell Technologies Inc. Micell Technologies™ is a biomedical company that is enhancing the performance of medical devices with innovative drug-delivery systems.   By applying its unique surface and polymer modification technologies, Micell can precisely and consistently control drug elution and the duration of polymer exposure creating the potential for a therapeutic solution for coronary artery disease without the long-term safety concerns of currently available drug-eluting stents. Micell is also developing a drug-coated balloon for vascular interventions.  Visit us at www.micell.com.

Micell, Micell Technologies, the Micell Logo, and MiStent are among the trademarks of Micell Technologies, Inc.Contact: Micell TechnologiesArthur J. Benvenuto, Chairman & CEO(919) 313-2104Media Contacts:Robert E. Flamm, Ph.D.Russo Partners(212) 845-4226

SOURCE Micell Technologies Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
2. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
3. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
4. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
5. New Clinical Studies Confirm Mauna Kea Technologies Cellvizio(R) GI in Range of Procedures
6. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
7. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
8. Senesco Technologies Initiates Preclinical Studies for Cancer Target
9. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
10. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
11. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... SAN FRANCISCO , Aug. 3, 2015  Sage ... generation of portable laboratory-quality cannabis potency measurement systems, announced ... PAC Bay Area Cruise Fundraiser. A limited number of ... the festivities and help a great cause while enjoying ... a scenic cruise around the San Francisco Bay at ...
(Date:8/3/2015)... -- Depomed, Inc. (NASDAQ: DEPO ) ("Depomed" or the ... HZNP ) ("Horizon") announcement that it intends to request ... record date to determine the shareholders eligible to request ... will review the request when it is received. Provided ... information required under Depomed,s bylaws, the Depomed Board will, ...
(Date:8/3/2015)... NEW YORK , August 3, 2015 /PRNewswire/ ... report published by Persistence Market Research "Global Market ... to Witness Highest Growth by 2022", ... at US$15 Bn by the end of 2015 and ... 6.8% from 2015 to 2022, to account for ...
Breaking Medicine Technology:Sage Analytics Sponsors California Cannabis Industry Association Bay Area Cruise FUNdraiser 2Depomed Comments on Horizon Pharma Announcement 2Depomed Comments on Horizon Pharma Announcement 3Depomed Comments on Horizon Pharma Announcement 4Depomed Comments on Horizon Pharma Announcement 5Depomed Comments on Horizon Pharma Announcement 6Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 2Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 3Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 4
... PRO-DEX, INC. (Nasdaq: PDEX ) invites investors and ... fiscal 2012 first quarter financial results. (Logo:   ... be broadcast live over the internet on Wednesday, November 9, ... and may be accessed by visiting the Company,s website at ...
... VIEW, Calif., Nov. 3, 2011 VIVUS, Inc. (NASDAQ: ... were published in Obesity, the peer-reviewed journal of The ... the investigational drug Qnexa in 1,267 severely obese (BMI >/= 35 ... addition to average weight loss of 14.4% of initial body weight ...
Cached Medicine Technology:Pro-Dex, Inc. Announces Fiscal 2012 First Quarter Financial Results Conference Call and Webcast 2Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment 2Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment 3Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment 4Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment 5Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment 6
(Date:8/3/2015)... Angeles, CA (PRWEB) , ... August 03, 2015 , ... ... Back Pain: Injection of Stem Cells Found to Release Natural Painkiller That Can Last ... pain in patients. According to the report, the new study showed that harvesting stem ...
(Date:8/3/2015)... ... August 03, 2015 , ... Illinois Health & Science (IHS) has completed ... The acquisition includes all of IBAM NA’s cyclotron sites and research and development facilities. ... regionally located business, as well as a large manufacturing hub in Noblesville, Indiana,” said ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... insurance brokerage firm, announced today that Joe Williams has joined its growing California ... and delivering HUB's differentiated service model to his clients. Mr. Williams will be ...
(Date:8/3/2015)... ... 03, 2015 , ... Cambia Health Solutions has promoted Scott ... company’s Medicare and Federal Employee Programs (FEP) lines of business. , Government ... members. In this role, Scott is responsible for overseeing the growth, finance and ...
(Date:8/3/2015)... ... August 03, 2015 , ... Examination ... and investigative services, has introduced a new logo and comprehensive brand strategy ... improve business outcomes for its customers. EMSI’s new tagline, “Powerful Information. Improved ...
Breaking Medicine News(10 mins):Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2Health News:Cambia Health Solutions Names Scott Powers President of Government Programs 2Health News:EMSI Announces New Branding: Powerful Information. Improved Outcomes. 2
... Mich., Dec. 10 GeneGo, Inc., a leading,provider of ... analysis ,today announced that A*STAR,s Singapore Immunology Network (SIgN) ... researchers will have access,to GeneGo,s MetaCore, training and advanced ... for all SIgN researchers. , ...
... in one resource the necessary information to make an informed decision when ... ... Lyndhurst, NJ (PRWEB) December 10, 2008 -- From picking a great pediatrician ... is), navigating the medical landscape can be a daunting task, especially if ...
... www.patheon.com , , ... Patheon (TSX:PTI), a global provider of drug development and ... to announce the opening of its new U.S. headquarters ... Triangle Park (RTP), North Carolina. , Established ...
... Trials and the Company,s Other Clinical Programs All Advanced During the ... Validation Achieved for Bavituximab and Peregrine,s Anti-PS Anti-Viral Platform in Nature ... Company Enters into Loan Agreement for Up to $10 Million in ... Dec. 10 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) ...
... , , TUCSON, Ariz., Dec. ... PRSC ) today announced that its Board of Directors has ... shareholders will receive rights to purchase shares of the Company,s ... , "In this period of unprecedented market volatility ...
... Consumers Advised to Secure Long Term Care Insurance While They,re ... KIRKLAND, Wash., Dec. 10 If you,ve put ... off a bit longer, anticipating the new administration,s health plan? ... Board of LTC Financial Partners LLC (LTCFP), one of the ...
Cached Medicine News:Health News:A*STAR's Singapore Immunology Network Is the First GeneGo Center of Excellence in Asia 2Health News:Vitals Launches Free eBook to Help Consumers Find "Dr. Right" 2Health News:Patheon Opens New U.S. Headquarters and Analytical Laboratory Facility in Research Triangle Park, NC 2Health News:Patheon Opens New U.S. Headquarters and Analytical Laboratory Facility in Research Triangle Park, NC 3Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 2Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 3Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 4Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 5Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 6Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 7Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 8Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 9Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 10Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 11Health News:Providence Service Corporation Adopts Shareholder Rights Plan 2Health News:Providence Service Corporation Adopts Shareholder Rights Plan 3Health News:Obama Health Plan Not Likely to Embrace Long Term Care, Industry Leader Says 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: